Florida CBD Market Insights under Farm Bill

Mar.04.2023
Florida CBD Market Insights under Farm Bill
Florida's CBD market grows after the "Farm Bill" passed in 2018, but regulations remain a challenge for industry insiders like Jordan.

Statement:


This article is solely focused on conducting research on related industries and foreign markets. It does not recommend any specific products and does not comment on any domestic policies related to the subject matter.


The legality of the products mentioned in the article only applies to their local overseas markets. Domestic readers are advised to take note and strictly adhere to relevant laws and regulations in China.


This article does not constitute any investment or consumption advice.


This article is not suitable for minors.


On the first day of the Asia Pacific Expo, 2FIRSTS conducted an exclusive interview with Jordan, a representative for CBD dealers in Florida. Jordan provided insights into the CBD market in the state of Florida.


The "Farm Bill" promotes the development of the marijuana market.


In 2014, the state of Florida passed the "Compassionate Medical Cannabis Act," which allowed some patients to use medical marijuana and low-THC cannabis.


What has truly fueled the booming CBD market in Florida is the Farm Bill introduced by the United States in 2018.


According to Jordan, this bill essentially opens the door for certain requirements to be met by marijuana products, with the most noteworthy aspect being the release of cannabinoids, including non-psychoactive cannabidiol (CBD), from federal regulation.


Jordan emphasized a key point to 2FIRSTS, stating that as long as the Delta-9 THC content is below 0.3%, it is classified as hemp rather than marijuana.


After the enactment of this law, products can be legally manufactured, sold, and transported as long as they comply with the federal regulations on ingredients limits and labeling requirements.


However, the implementation of regulations in different states may vary. For example, Florida has stricter regulations regarding marijuana. "First, one must have a lab that has a QR code to test all substances in the sample, including the levels of THC and CBD in marijuana, as well as testing for mold, heavy metals, and pesticides," said Jordan.


You never know when new regulations may be implemented.


Although there are existing regulations at the macro level, government regulation in response to the development of the CBD market is not set in stone and will be adjusted over time as new issues arise. For distributors like Jordan, it is important to ensure clear and transparent product ingredients and avoid any gray areas or potential bans.


Jordan stated, "Because you never know when there will be new regulations. The regulatory authorities could change the rules as early as tomorrow.


In recent years, the United States has become increasingly tolerant towards recreational marijuana. Jordan himself holds an optimistic view towards the potential future legalization of recreational marijuana in Florida, believing that it's only a matter of time. Data seems to support his optimistic outlook - as of February 2023, 21 states and Washington D.C. have legalized recreational marijuana, a stark contrast to the zero states that had done so prior to November 2011.


How will the market develop in the future?


From the perspective of someone who is focusing on CBD products, the rapid changes in the US consumer market are even difficult for industry insiders to predict. He cited the example of the rise of psychedelic mushrooms in the US market last year. Prior to this, there had never been such a product on the market, and no one could have predicted the emergence of this dark horse.


Jordan stated, "The industry is increasingly turning to psychedelic mushrooms and other alternative smoking products, while consumers are also placing greater attention on health.


According to Jordan, the CBD market in Florida has great potential for growth, especially with the gradual relaxation of marijuana regulations and increased awareness among consumers of health benefits. This may lead to an emergence of more innovative products and demand in the market.


However, for industry professionals, the challenge of operating in a constantly changing regulatory environment remains significant. Regardless of how the market may shift in the future, Jordan states that his focus will always be on providing high-quality CBD products to consumers.


2FIRSTS will continue to cover the APE exhibition and we look forward to bringing you the latest updates and reports.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Product | KUMI SCENIC 50K Offers Nicotine and 6-Methyl Nicotine Versions as 6-MN Products Appear in Multiple U.S. State Directories, With Louisiana Listing FDA Exemption
Product | KUMI SCENIC 50K Offers Nicotine and 6-Methyl Nicotine Versions as 6-MN Products Appear in Multiple U.S. State Directories, With Louisiana Listing FDA Exemption
An October 2026 review of U.S. state vapor product directories found KUMI 6 SCENIC 50K listed in Louisiana and Nebraska. Louisiana classifies 20 related product entries as “FDA EXEMPTION.” The SCENIC platform is marketed in both conventional nicotine-salt and NoNic6 formulations, each advertised with 22mL e-liquid capacity and up to 50,000 puffs. U.S. wholesaler Midwest Goods listed both versions in August 2025 with a suggested retail price of $19.99 each. The NoNic6 version is associated with 6-methylnicotine and is also marketed by some distributors as “nicotine-free.”
product
Oct.27
PMI Launches Fourth IQOS Convenience-Store Discount of 2026 for Black Friday in Japan, Cutting ILUMA i ONE to About $19 After Ploom AURA Fell to About $9
PMI Launches Fourth IQOS Convenience-Store Discount of 2026 for Black Friday in Japan, Cutting ILUMA i ONE to About $19 After Ploom AURA Fell to About $9
Philip Morris Japan launched its fourth confirmed nationwide convenience-store discount campaign for IQOS ILUMA i devices in 2026 on October 26, cutting three models by as much as ¥2,000, or about $12.70. The campaign began one day after JT ended a promotion that reduced Ploom AURA to ¥1,480, or about $9.40. JT says Ploom's share of Japan's heated-products category rose from 10.9% in January 2024 to 18.3% in June 2026, a gain of 7.4 percentage points, while PMI says IQOS still held about 68% category share in the third quarter. At the same time, Japan's two-stage heated-tobacco tax adjustment has pushed stick prices higher, leaving device discounts as an increasingly important tool for lowering the upfront cost of customer acquisition.
Market
Oct.28
Special Report | Altria's NACS Booth Raises Questions Over U.S. Tobacco Advertising Warnings
Special Report | Altria's NACS Booth Raises Questions Over U.S. Tobacco Advertising Warnings
During its coverage of Altria's booth at NACS Show 2026, 2Firsts documented product displays that prompted questions about U.S. tobacco advertising warning requirements. Following public comments from a former FDA official, 2Firsts sought responses from Altria and independently consulted U.S. regulatory lawyer Azim Chowdhury. Altria maintained that its B2B communications complied with applicable laws, while Chowdhury explained that federal warning rules provide no general trade-show exemption for e-cigarettes and nicotine pouches. The special report examines the broader regulatory implications.
Nov.04
Special Report | Can Nicotine Be Replaced? 6-MN Is Already on the Market While Key Human Evidence Is Still Missing
Special Report | Can Nicotine Be Replaced? 6-MN Is Already on the Market While Key Human Evidence Is Still Missing
Nicotine analogues such as 6-methylnicotine are already appearing in e-cigarettes and oral pouches, even as key human evidence remains limited. A new Nixodine-S study adds nonclinical data showing differences from nicotine in cytotoxicity and receptor activity, while independent studies point to a more complex toxicological picture. With supply-chain activity growing and FDA seeking clearer authority over nicotine analogues, the industry now faces a larger question: what evidence is needed before these substances can credibly replace nicotine?
SCIENCE
Sep.23
South Korea Fully Reviews Nicotine-Analog and Nicotine-Free Vape Liquid Imports, With Over 99% From China and Chinese Supply-Chain Documents Under Scrutiny
South Korea Fully Reviews Nicotine-Analog and Nicotine-Free Vape Liquid Imports, With Over 99% From China and Chinese Supply-Chain Documents Under Scrutiny
Korea Customs Service has tightened import controls on nicotine-analog and nicotine-free e-cigarette liquids, placing the products under 100% document review and subjecting all e-cigarette liquid import declarations to pre-clearance ingredient analysis. As of September 20, 2026, South Korea had imported about 15 metric tons of nicotine-analog liquids, 99.99% from China, and about 316 metric tons of nicotine-free liquids, including roughly 315 metric tons, or 99.7%, from China. The measures follow South Korea's April expansion of its tobacco definition to include synthetic nicotine products and include new checks on Chinese manufacturing, transaction and export documentation.
Sep.24
JTI Invests ₱2.1 Billion to Upgrade Batangas Manufacturing Hub, Adds First Southeast Asia DIET Facility
JTI Invests ₱2.1 Billion to Upgrade Batangas Manufacturing Hub, Adds First Southeast Asia DIET Facility
JTI Asia Manufacturing Corp. has invested ₱2.1 billion, or about $37 million, in its manufacturing site in Malvar, Batangas, Philippines, to expand tobacco-processing capabilities. About ₱1.9 billion is allocated to JTI's first Dry Ice Expanded Tobacco, or DIET, facility in Southeast Asia, while more than ₱177 million has been spent on expanding its Controlled Atmosphere treatment facility. The Batangas plant supplies the Philippine market and exports to 22 overseas markets, making it one of JTI's key manufacturing hubs in Asia.
Sep.24